CVM Stock Forecast: CEL-SCI Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for CEL-SCI Corp. is $13. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CEL-SCI Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CVM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CVM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 July 2023 | EF Hutton | Reiterates | Buy | — |
| 9 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 17 Feb 2023 | EF Hutton | Assumes | Buy | $10 |
| 29 Dec 2022 | EF Hutton | Maintains | Buy | — |
| 25 Aug 2022 | EF Hutton | Initiates | Buy | — |
| 7 Apr 2022 | EF Hutton | Initiates | Buy | — |
| 13 Jan 2020 | H.C. Wainwright | Initiates | Buy | — |
| 13 Jan 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 20 Feb 2013 | Taglich Brothers | Initiates | Speculative Buy | — |
| 13 Feb 2013 | Chardan Capital | Initiates | Buy | — |
| 14 Jan 2013 | Laidlaw & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CVM.
This page is one stock. Monday covers all of them.
CVM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CVM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CEL-SCI Corp. returned −80.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CVM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 42% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −252.5%
- Return on assets
- −66.8%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CEL-SCI Corp. has a market value of $25.9M and an enterprise value of $27.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$22.7M.
Free cash flow in the twelve months to 30 June 2026: −$16.8M.
Data provided by Twelve Data
CVM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CVM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CEL-SCI Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CVM
What is the CVM stock price forecast for 2026-2027?
The median 12-month analyst price target for CEL-SCI Corp. is $13, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CVM stock a buy right now?
Of the 2 analysts covering CEL-SCI Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CEL-SCI Corp. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CVM?
As at 21 Nov 2026, CEL-SCI Corp. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
Will CVM stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $13, and Ticker Nerd's factor model ranks CEL-SCI Corp. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CVM stock forecast for 2030?
No analyst covering CEL-SCI Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.
How has CVM stock performed over the past year?
CEL-SCI Corp. returned -80.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CEL-SCI Corp. do?
CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and infectious diseases. Its principal investigational therapy, Multikine, is designed to activate and coordinate the immune system around the treatment of certain cancers, with research centered on improving outcomes through an integrated immune response.
About CEL-SCI Corp.
CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and infectious diseases. Its principal investigational therapy, Multikine, is designed to activate and coordinate the immune system around the treatment of certain cancers, with research centered on improving outcomes through an integrated immune response. The company also develops its Ligand Epitope Presentation System, or LEAPS, a platform intended to help direct immune responses toward disease-specific targets. CEL-SCI’s activities span biotechnology research, clinical development, pharmaceutical manufacturing, and regulatory preparation, positioning it within the specialized biopharmaceutical market. Its work addresses significant healthcare sectors, including oncology and infectious disease treatment, where immune-based approaches are an important area of medical research. Headquartered in Vienna, Virginia, CEL-SCI Corporation represents a development-focused biotechnology business whose market role is tied primarily to advancing investigational therapies and proprietary immune-modulation technologies rather than selling a broad portfolio of commercial medicines.
CEO Mr. Geert R. Kersten Esq. · United States · https://cel-sci.com